Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.

Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Abstract Text:

Hai Liang Zhang,Ding Wei Ye,Xu Dong Yao,Bo Dai,Shi Lin Zhang,Yi Jun Shen,Yao Zhu,Wen Zhang,Hai Liang Zhang,Ding Wei Ye,Xu Dong Yao,Bo Dai,Shi Lin Zhang,Yi Jun Shen,Yao Zhu,Wen Zhang,Hai Liang Zhang,Ding Wei Ye,Xu Dong Yao,Bo Dai,Shi Lin Zhang,Yi Jun Shen,Yao Zhu,Wen Zhang,

PURPOSE: To preliminarily investigate the efficacy of docetaxel plus prednisone and mitoxantrone plus prednisone for treating metastatic hormone-refractory prostate cancer and to further evaluate its adverse events in Chinese patients. MATERIALS AND METHODS: 83 patients with metastatic hormone-refractory prostate cancer were enrolled in the trial and given a combination of docetaxel 75 mg/m(2) intravenously on day 2 or mitoxantrone 12 mg/m(2) on day 1 plus prednisone 5 mg twice daily on days 1-21, 21 days a cycle. Serum PSA level, relief of bone pain, myelosuppression, and vomiting were recorded and calculated. RESULTS: Docetaxel plus prednisone was administered to 44 patients: 13.6% (6/44) of them achieved complete response, 29.5% (13/44) partial response, 29.5% (13/44) had stable disease, and 27.3% (12/44) had disease progression. The average time to PSA progression was 37.8 weeks (12-101 weeks) in the response and stable disease patients. The 12 patients with disease progression were given MP as salvage therapy, and 16.7% (2/12) achieved a partial response, 25.0% (3/12) had stable disease and formed the new baseline. Only 2 patients died of disease aggravation. Mitoxantrone plus prednisone were given to 39 patients, and 7.7% (3/39) of them achieved complete response, 25.6% (10/39) partial response, 25.6% (10/39) had a stable disease, and 41.0% (16/39) of patients had disease progression. The mean time to PSA progression was 25.3 weeks (8-61 weeks) in the response and stable disease patients. The 14 patients with disease progression were administered DP as a salvage therapy and 7.1% (1/14) achieved complete response, 35.7% (5/14) partial response, and 21.4% (3/14) had stable disease and formed the new baseline. Four patients had died at the last follow-up. CONCLUSIONS: In Chinese patients, docetaxel plus prednisone is better than mitoxantrone plus prednisone in PSA response rate and PSA control, but has a bit more toxicity. When the tumor is resistant to one regimen, the other might still be effective in controlling disease progression.

Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Publishing Authors By Initials

HL Zhang,DW Ye,XD Yao,B Dai,SL Zhang,YJ Shen,Y Zhu,W Zhang,HL Zhang,DW Ye,XD Yao,B Dai,SL Zhang,YJ Shen,Y Zhu,W Zhang,HL Zhang,DW Ye,XD Yao,B Dai,SL Zhang,YJ Shen,Y Zhu,W Zhang,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Urologia internationalis

VOLUME: 79

Page Numbers: 307-11

Journal Abbreviation: Urol. Int.

ISSN: 1423-0399

DAY: 20

MONTH: 11

YEAR: 2007

Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 417373

Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.

AFFILIATION: Department of Urology, Cancer Hospital, Fudan University, Shanghai, PR China.

Country: Switzerland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Urol Int

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center Related Publications

• A comparative study on the intercuspal occlusion among TMD patients, malocclusion patients and university students.
• Effect of retinoblastoma gene on human osteosarcoma cell line OS732.
• Enhanced antioxidant and cytoprotective abilities of vitamin E succinate is associated with a rapid uptake advantage in rat hepatocytes and mitochondria.
• Intervention by azithromycin on bleomycin-induced lung injury in rats and its mechanisms.
• Method development of adsorbed stationary phase open tubular capillary electrochromatography.
• Supercritical fluid CO2 extraction of colchicine from colchicine Autumnele liliaceae.
• Vascular endothelial growth factor gene expression in patients' ischemic skeletal muscle with diabetic foot.
• [A case of hypodermiasis with empyema]
• [Analysis of hepatitis G virus genotypes in some areas of China]
• [Autologous dendritic cells eliciting cytotoxicity of bone marrow cells against chronic granulocytic leukemia]
• [Changes of human recombination bone morphogenetic protein-2 in bone and marrow in tail suspended rats]
• [Cloning of the mouse Doc-1R gene by genomic walking]
• [Construction of recombinant adenoviruses carrying human urokinase-type plasminogen activator and its expression in hepatic stellate cells in vitro]
• [Effect of inhibition of telomerase activity on cisplatin-induced apoptosis in K562 cells]
• [Effects of electrical stimulation of lateral hypothalamic area on gastric ischemia-reperfusion injury in rats]
• [Fatal complications in traffic accident injury]
• [Indomethacin induces apoptosis of K562 cells through activation of caspases and elevation of intracellular free calcium]
• [Infection and replication of hepatitis B virus and its clearance mechanism: an overview]
• [Mechanisms underlying dopaminergic neurotoxicity in ischemic cerebral damage]
• [Physiological and pathologic implications for zero-stress state of the esophagus]
• [Protein kinases and Alzheimer's disease]
• [Retroperitoneal laparoscopic unroofing of renal cyst: use of close method]
• [Risk of leukemia among medical X-ray workers in China between 1950 and 1995]
• [Studies on association between lipoprotein lipase gene polymorphisms of Pvu II site and hypertriglyceridemics in Chinese]
• [Study on automatic segmentation of color images applied to blood cells]
• [Study on high performance liquid chromatography/indirect photometric detection of fosfomycin with acridine as detection reagent]
• [Study on the application of number fluorescence density in detecting autoantibodies titer]
• [The effects of surface morphology of calcium phosphate ceramics on apatite formation in dynamic SBF]
• [Transforming growth factor beta(1) and bone morphogenetic protein 2 induce the differentiation of odontoblasts in vitro]
• [Vector propagation algorithm based ECG simulation of bundle branch block]